Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Cardiovascular diseases are the leading cause of morbidity and mortality worldwide, frequently elicited by acute coronary syndromes (ACS). Over the past decades, numerous large-scale randomised clinical trials have demonstrated the benefits of several interventions for the care of patients with ACS, including antiplatelet therapy, anticoagulation, and urgent or emergent cardiac catheterisation followed by revascularisation as appropriate. As a result, an increasing array of evidence-based cardiac medications and interventions have been rapidly adopted worldwide, fostered by multiple practice guidelines providing clear recommendations for clinicians.1 ,2
Recent evidences suggest that these remarkable advancements were associated with a significant decline in mortality from cardiovascular diseases in the recent years, more pronounced in high-income regions (especially Australasia, Western Europe and North America).3 Nonetheless, there are still marked disparities, with respect to the epidemiology, diagnostics and treatment of such patients with ACS, also leading to various morbidity and mortality rates throughout the globe. In this regard, a large number of prospective registries worldwide have been conducted over the last years in the context of ACS, aiming to provide standardised regional data to physicians, institutions and policy makers. The EURHOBOP registry (EURopean HOspital Benchmarking by Outcomes in acute coronary syndrome Processes) …
Contributors Both authors have read and approved submission of the manuscript. Both authors have contributed to this work as follows: (1) substantial contributions to the conception and design, acquisition of data or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be published.
Funding HBR is supported by a research PhD grant from The National Council for Scientific and Technological Development (CNPq), Brazil. PAL is supported in part by a Researcher grant from CNPq.
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.